selective TGFβR1 kinase inhibitor

completed oral CV studies in higher species

from data mining of internal matter and opt.

ACS Med. Chem. Lett. 11, 172-178

Bristol-Myers Squibb, Princeton, NJ

BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.